A5075735855- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Hepatitis C virus research
- Organ Transplantation Techniques and Outcomes
- Gastroesophageal reflux and treatments
- Multiple Sclerosis Research Studies
- Multiple Myeloma Research and Treatments
- Mycobacterium research and diagnosis
- Ginseng Biological Effects and Applications
- Polyomavirus and related diseases
- Plant Virus Research Studies
- Drug-Induced Hepatotoxicity and Protection
Hospital South West Jutland
2020-2024
The prevalence of minimal hepatic encephalopathy (MHE), in particular different subgroups, remains unknown. This study aimed to analyze the MHE subgroups identify patients at high risk and pave way for personalized screening approaches.In this study, data recruited 10 centers across Europe United States were analyzed. Only without clinical signs included. was detected using Psychometric Hepatic Encephalopathy Score (PHES, cut-off < or ≤-4 depending on local norms). Clinical demographic...
Abstract Background and aims Minimal hepatic encephalopathy (MHE) is a frequent complication in patients with liver cirrhosis. Its impact on predicting the development of overt (OHE) survival has not been studied large multicenter studies. Methods Data from recruited at eight centers across Europe United States were analyzed. MHE was detected using psychometric score (PHES). A subset also tested simplified animal naming test (S‐ANT1). Patients followed for OHE death/liver transplantation...
Background & AimsData on the association between proton pump inhibitor (PPI) use and hepatic encephalopathy (HE) are conflicting, data from multicenter studies scarce. The aim of this study was to dissect potential PPI minimal (MHE) overt HE (OHE).MethodsData patients with cirrhosis recruited at seven centers across Europe US were analyzed. MHE defined by Psychometric Hepatic Encephalopathy Score (PHES). recorded day testing PHES. Patients followed for OHE development death/liver...
Diroximel fumarate (DRF) is a new emerging therapy for patients with multiple sclerosis. The levels of its active metabolite, monomethyl fumarate, are bioequivalent to the generated from dimethyl (DMF) treatment. efficacy and safety profiles DRF expected be similar well-established DMF. metabolism leads lower concentration methanol in small intestine than DMF thus reduced severity frequency gastrointestinal adverse events. seems promising alternative other first-line therapies current review...
This paper demonstrates a case of progressive multifocal leukoencephalopathy (PML) in patient with multiple myeloma (MM) treated nine different MM therapies. report contributes to the already published 16 cases PML patients MM. Additionally, this presents an analysis from United States Food and Drug Administration Adverse Event Report System database (n = 117) description demographics MM-specific Patients MM, that developed PML, were immunomodulatory drugs (97%), alkylating agents (52%),...
Background: Minimal hepatic encephalopathy, defined by the portosystemic encephalopathy score (PHES), is associated with a higher risk of subsequent OHE. It remains unclear if there stepwise increase in OHE worse PHES results. Methods: In this multicenter study, patients minimal as abnormal PHES, were followed for development. Results: all, 207 included. There was no Conclusions: Abnormal risk, but we found results below established cutoff.
Background: Minimal hepatic encephalopathy (MHE) is a common complication in patients with cirrhosis, and its prevalence increases poorer liver function. Aim: To analyze the association of MHE development OHE, transplantation (LTx), or death large multicenter study cohort. Methods: Data from 8 centers across Europe US were included. was diagnosed by PHES. A subgroup also tested Animal Naming Test (S-ANT1). Patients followed for OHE development, death, LTx. Results: total 1462 median MELD 11...
Einleitung Die minimale hepatische Enzephalopathie (MHE) ist eine häufige Komplikation bei PatientInnen mit Leberzirrhose. Der Einfluss der MHE auf das Risiko für die Entwicklung einer overten HE (OHE) im Verlauf und Prognose wurde bisher nur in kleineren Studien untersucht.
Background: Hepatic encephalopathy (HE) is a frequent complication of liver cirrhosis and common reason for hospital admission readmission. There are no available risk scores to predict the development HE, but Bilirubin-Albumin-Beta-Blocker-Statin (BABS) score has been proposed as tool stratification. The aim study was validate BABS prediction HE in patients with cirrhosis. Methods: Patients from Mainz, Germany without baseline (n = 398) were included. primary outcome defined grade ≥1...